Answers are grounded in this paper and cite their sources.
Increased concentrations of urinary α1-microglobulin may imply proximal tubular damage (1). α1-Microglobulin has generally been considered to be stable in human urine (1)(2). Tencer et al. (2) observed good stability in 10 urine samples stored at room temperature for 7 days, at 4 °C for 30 days, and at −20 °C for 6 months. In contrast, Donaldson et al. (3) noted significant losses of α1-microglobulin in urine stored at −20 °C and that this problem was exacerbated in more acidic (pH <6.0) urines; they recommend that urine should be neutralized on receipt. The manufacturers of our assay recommend that urines be assayed fresh or stored at 4 °C for a period of less than 1 week and warn against freezing samples. Urine samples are often stored before batch analysis. To clarify the appropriate storage conditions for urinary α1-microglobulin, we studied stability under standardized conditions. Random unpreserved urine samples were collected from 19 patients at a single nephrology clinic, and urinary pH was determined (mean pH 5.87; range, 5.08–6.85). Samples were then divided into two aliquots, one of which was neutralized (mean pH 7.58; range, 7.23–7.94) by dropwise addition of 5 mol/L NaOH. Within 6 h of collection, α1-microglobulin and creatinine were measured in both aliquots. Ten (≈1 mL each) aliquots of both the untreated and neutralized urines were stored in capped polystyrene tubes at room temperature, 4 °C, −20 °C, or −80 °C for periods of time from 24 h to 6 months (Table 1). Before analysis, samples were equilibrated to room temperature, mixed by inversion, and left to settle under gravity for 5 min (i.e., not centrifuged). Each aliquot was subjected to only a single freeze-thaw cycle. Effect of sample storage conditions on urinary α1-microglobulin concentration. Samples were initially assayed within 6 h of collection, both before (F) and after (FA) neutralization. They were reanalyzed after storage at room temperature, 4 °C, −20 °C, and −80 °C for periods of time from 24 h to 6 months, and each treatment was compared against its respective baseline sample (i.e., against F or FA). CI, confidence interval; RT, room temperature. P <0.01 compared with treatment F. P <0.01 compared with treatment FA. Effect of sample storage conditions on urinary α1-microglobulin concentration. Samples were initially assayed within 6 h of collection, both before (F) and after (FA) neutralization. They were reanalyzed after storage at room temperature, 4 °C, −20 °C, and −80 °C for periods of time from 24 h to 6 months, and each treatment was compared against its respective baseline sample (i.e., against F or FA). CI, confidence interval; RT, room temperature. P <0.01 compared with treatment F. P <0.01 compared with treatment FA. Urinary α1-microglobulin was measured by rate immunonephelometry on an ImmageTM analyzer (Beckman Coulter Ltd.) using a goat anti-human α1-microglobulin antibody. The assay was standardized using the manufacturer’s calibrant (target value, 40.2 mg/L). The limit of detection of the assay was 4 mg/L. The within-day imprecision (CV) determined using 18 replicates of both a patient’s urine (mean value, 7.4 mg/L) and the manufacturer’s control material (mean value, 14.7 mg/L) was <2.0%. Between-day imprecision during the study period, determined with the manufacturer’s control material, was 3.7% (n = 22). Urinary creatinine was measured using a Jaffe method on a Cobas Mira S Plus analyzer (Roche Diagnostics Ltd.). The addition of NaOH significantly diluted the neutralized aliquots, as demonstrated by lower urinary creatinine concentrations (mean, 10.3 vs 9.9 mmol/L; P <0.01). Results were therefore analyzed for differences between storage conditions, using two separate Friedman analyses of variance for the untreated and neutralized urine data sets. The Wilcoxon matched-pairs signed-rank test was used to test for differences within data sets by comparing each treated sample against its respective baseline sample (i.e., against either F or FA in Table 1). P <0.01 was considered significant. In the absence of a recognized reference preparation for urinary α1-microglobulin, assay commutability was demonstrated by estimating an upper reference limit (0.95 percentile) for the urinary α1-microglobulin/creatinine ratio, using a nonparametric approach (4). Random urine samples were collected from 80 healthy volunteers with no history of renal disease (52 females and 28 males; mean age, 39.1 years; median age, 40 years; range, 20–65 years). Samples were stored at −20 °C for less than 1 week before analysis. Urinary α1-microglobulin was undetectable in 26 samples, in keeping with the observations of Jung et al. (5). The upper reference limit was 1.5 mg/mmol of creatinine, in close agreement with others (5)(6)(7), although somewhat higher than that derived by Tencer et al. (8). All patients and healthy volunteers had the study explained to them and gave informed consent. The study had full approval of the local research ethics committee. Some differences were observed in measured α1-microglobulin concentrations in both untreated (Friedman statistic, 59.2; P <0.0001) and neutralized urines (Friedman statistic, 81.4; P <0.0001; Table 1). This was attributable to significant changes in treatment groups 1, 2, 4, 8, 9, 1A, 2A, 7A, and 9A as a consequence of between-assay variation (although the assay remained in control throughout the study). The median differences observed were <4 mg/L under all storage conditions. However, two specimens did show appreciable losses (>40%) at −20 °C irrespective of neutralization. The urinary α1-microglobulin concentration was stable at −80 °C for up to 6 months irrespective of whether samples were neutralized. Our data are consistent with those of Tencer et al. (2) in suggesting that α1-microglobulin is stable in urine for at least 24 h at room temperature and up to 1 month at 4 °C. Ideally, however, we would recommend that longer-term storage (beyond 2 months) should be at −80 °C. In our hands, α1-microglobulin demonstrated excellent stability in human urine ex vivo, and neutralization was not necessary to ensure sample integrity. Consequently, samples can be conveniently handled by diagnostic laboratories with reasonable confidence that any increased excretion of α1-microglobulin will be detected. We are grateful to Beckman-Coulter Ltd. (High Wycombe, United Kingdom) for providing the reagents for this study. D. Smith of the Department of Clinical Biochemistry provided expert technical assistance.
No takes yet. Share an insight, caveat, or question.
Payn et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: